Voyager to showcase two tau therapies at CTAD 2026
Voyager Therapeutics announced two poster presentations at the 19th Clinical Trials on Alzheimer’s Disease conference in Boston, scheduled for 16-19 November 2026. The posters will highlight VY1706, an investigational gene therapy designed to lower tau production in the brain, and VY7523, a clinical
<p>Voyager Therapeutics announced two poster presentations at the 19th Clinical Trials on Alzheimer’s Disease conference in Boston, scheduled for 16-19 November 2026. The posters will highlight VY1706, an investigational gene therapy designed to lower tau production in the brain, and VY7523, a clinical</p>